HBW Insight - News And Expert Analysis On The Consumer Healthcare Industry since 1980

Huge opportunities for OTC therapies loom in India, as consumerization brings structural reset in healthcare. Success stories on Rx-to-OTC transition augur well for pharma, but a predictable regulatory roadmap will be pivotal for sustainable growth.

Industry associations in the UK, Germany and Greece expect 2026 to be the year self‑care policy is translated into day‑to‑day system change. They highlight opportunities in pharmacy, digital tools and regulatory reform, but warn that progress depends on political timing and regulatory agility.

Both companies announced that during special meetings on Jan. 29, their shareholders voted nearly unanimous support for Kimberly-Clark’s $48.7bn acquisition proposed in November at $3.50 per share plus 0.14625 share for each Kenvue share.

New York-based Revlon was able to demonstrate substantiation for two claims for its namesake ColorSilk with bond Repair Complex hair color, while committing to modifying or discontinuing several other claims that the National Advertising Division concluded were not supported.

The France-based dietary supplements firm is targeting sales in excess of €25m next year.

Changing self-GRAS regulation, providing NDIN safety and identity guidance and modernizing supplement industry regulatory framework are on FDA’s “2026 priority deliverables,” but not requirement for public listing of all supplements available.